Evidence map›Paper›PMID 42291184›Full record

ArticleiScience2026

ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance.

Yun Huang, Yu Zhao, Ping Yan, Zhiquan Long, Chuang Xia, Ling Jiang, Yujiao Zhang, Jiaying Cheng, Fang Liu, Quan Wu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yun HuangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yu ZhaoDepartment of Hematology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510515, China.
Ping YanDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Zhiquan LongDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Chuang XiaInnovation Program of Drug Research on Neurological and Metabolic Diseases, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Ling JiangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yujiao ZhangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Jiaying ChengDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Fang LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Quan WuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Zhongzhen ZhouInnovation Program of Drug Research on Neurological and Metabolic Diseases, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Xuejie JiangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoresistance in acute myeloid leukemia (AML) is associated with a poor prognosis in patients. Ferroptosis is one of the mechanisms by which anthracycline exerts anti-leukemic effects, with drug-resistant AML cells exhibiting increased resistance to ferroptosis. Elevated expression of aldehyde dehydrogenase 3 family member A2 (ALDH3A2) is correlated with poor prognosis in patients with AML. Patients with chemo-resistant AML exhibit higher levels of ALDH3A2, particularly the V subtype. ALDH3A2 degraded 4-hydroxynonenal and regulated the fatty acid proportion and content of AML cells, protecting AML cells against doxorubicin-induced ferroptosis. Moreover, overexpression of ALDH3A2 changes cell membrane fluidity and reduces drug uptake. Histone deacetylase 2 binds to the ALDH3A2 promoter and regulates its expression. The inhibition of ALDH3A2 or HDAC enhances chemotherapeutic efficacy in AML.

Indexed as

CancerMolecular networkTherapeutics

Identifiers

PMID42291184
PMCPMC13254865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.